NCT Number: NCT05049044
OBSTINATE is an observational, national, prospective, multicentric study on Quality of life in patients with unresecable stade III non-small cell lung cancers.
Locally advanced non-small cell lung cancers (NSCLCs with a Tumor, Node and Metastasis [TNM] stage III) patients represent approximately a third of newly discovered NSCLCs every year, and a very heterogeneous group of clinical situations. Therapies are multidisciplinary and very heterogeneous across oncology centers. Patients with locally advanced NSCLC have a high symptom burden that is known to affect their quality of life. Health-related quality of life (HR-QoL) is a specific and multidimensional type of patient-reported outcome (PRO) related to the physical, psychological and social impact of the disease and its treatment as perceived by patients. HR-QoL allows, together with data of efficacy and safety, a more complete assessment of risks and benefits of each treatment. Therefore, QoL maintenance is a valuable consideration for treatment decisions, especially in the rapidly evolving therapeutic landscape of unresectable NSCLC.
The study is designed to collect PROs HR-QoL data from every new patient diagnosed with an unresectable stage III NSCLC over a period of 18 months. We also aim to describe clinical characteristics of these patients, the therapeutic strategies conducted, and outcomes in a "real-word" oncological practice.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Centre Hospitalier d'Aix en Provence, Aix-en-Provence, France
OBSTINATE is an observational, prospective, national, multicentric study conducted in patients newly diagnosed with an unresectable stage III NSCLC (with exclusion of early stages NSCLC classified to pathological stage III).
OBSTINATE is a study planned to include 450 patients between 50 to 70 GFPC-affiliates or GFPC-associated centers approximately. All centers are located in France. The participating Site Investigators will be treating physicians within one of the participating centers.
After screening for eligibility checks, patients will receive the Patient Information Note from the Site Investigators. This Patient information Note will describe the study purpose and modalities. Patients who meet the eligibility criteria and do not oppose to data collection will be enrolled. The schedule of the medical visits in the study center will depend on the patient and his/her routine clinical care Protocol-relevant data will be collected by the treating physician within each center, for up to 5 years following the last patient's enrollment in the study.
Patients included in the study will complete the self-assess questionnaires at enrollment and during routine care follow-up, according to pre-specified data collection schedule.
Usual practices or modalities of follow-up of patients will remain unchanged compared to the current clinical practice as the study is designed to provide descriptive summary information.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
Other names: Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L)
Time frame: Up to 6,5 years (18 months of recruitment + 5 years). For Cohort 1 & 2, a follow-up post progression is planned
Change in patient's QLQ-C30 during treatment and follow-up until confirmed progression, loss of follow-up or end of the study compared to Baseline in patients diagnosed with unresectable stage III NSCLC in a "real-world" oncological practice.
This evaluation is based on self-assess questionnaire distributed to the patients according to pre-specified data collection schedule.
The primary objective will be addressed in the cohort as a whole, and independently for every cohort of interest.
Time frame: Up to 6,5 years (18 months of recruitment + 5 years). For Cohort 1 & 2, a follow-up post progression is planned
Change in patient's QLQ-LC13 during treatment and follow-up until confirmed progression, loss of follow-up or end of the study compared to Baseline in patients diagnosed with unresectable stage III NSCLC in a "real-world" oncological practice.
This evaluation is based on self-assess questionnaire distributed to the patients according to pre-specified data collection schedule.
The primary objective will be addressed in the cohort as a whole, and independently for every cohort of interest.
Time frame: Up to 6,5 years (18 months of recruitment + 5 years). For Cohort 1 & 2, a follow-up post progression is planned
Change in patient's EQ5D-5L during treatment and follow-up until confirmed progression, loss of follow-up or end of the study compared to Baseline in patients diagnosed with unresectable stage III NSCLC in a "real-world" oncological practice.
This evaluation is based on self-assess questionnaire distributed to the patients according to pre-specified data collection schedule.
The primary objective will be addressed in the cohort as a whole, and independently for every cohort of interest.
Time frame: At Baseline
Stage III unresectable NSCLC patients characteristics: baseline patient demographics at stage III NSCLC diagnosis, clinical, pathological and molecular characteristics (e.g. age, race, comorbidities)
Time frame: At Baseline
Characterize the stage III unresectable NSCLC patients by TNM stage according to the 8th TNM IASLC edition
Time frame: At Baseline
Characterize the stage III unresectable NSCLC patients by PD-L1 expression status (tumor propensity score)
Time frame: At Baseline
Characterize the stage III unresectable NSCLC patients by mutational status of driver genes (e.g. epidermal growth factor receptor [EGFR]) anaplastic lymphoma kinase [ALK], reactive oxygen species 1 [ROS1], human epidermal growth factor receptor 2 [HER2], PI3KCA, BRAF, MET, rearranged during transfection [RET], neurotrophic receptor tyrosine kinase [NRTK])
Time frame: From date of diagnosis until the date of first documented treatment or start date of best supportive care through study completion, up to 5 year
Time frame: From date of diagnosis until the date of first documented progression or or date of death from any cause, whichever came first, assessed up to 5 years maximum
Description of modality of follow-up (e.g. type of imagery used, frequency of medical visit)
Time frame: From date of first treatment administration up to first documented disease progression and/or death from any cause, whichever came first, assessed up to 60 months
Time from date of first treatment administration until the date of first documented progression or date to death from any cause, whichever came first as evaluated by investigators.
Time frame: From date of first treatment administration up to first documented disease progression and/or death from any cause, whichever came first, assessed up to 60 months
Time from date of first treatment administration until the date of first documented progression or date to death from any cause, whichever came first as evaluated by investigators.
Time frame: From date of first treatment administration up to first documented disease progression and/or death from any cause, whichever came first, assessed up to 60 months
Time from date of first treatment administration until the date of first documented progression or date to death from any cause, whichever came first as evaluated by investigators.
Time frame: From date of first treatment administration up to end of study, assessed up to 5 years maximum
Describe the chemotherapy, radiation therapy and immunotherapy protocols used (e.g. dose, reduction, interruptions, duration)
Time frame: From date of first treatment administration up to end of study, assessed up to 5 years maximum
Time frame: From date of first treatment administration up to end of study, assessed up to 5 years maximum
Time frame: From date of first treatment administration up to end of study, assessed up to 5 years maximum
limited to Cohorts 1, 2, 3 and 4 (restricted to significant AEs, which include but are not limited to: serious AEs [SAEs], AEs that led to treatment discontinuation, or any AEs ≥ grade 3 judged clinically significant by the Site Investigator)
Time frame: From date of first treatment administration up to end of study, assessed up to 5 years maximum
Concordance between effective treatment compared to initial MDTB decision
Time frame: At date of first documented progression, assessed up to 5 years maximum
Time frame: From date of first documented progression up to end of study, assessed up to 5 years maximum
Treatment characteristics after disease progression including type of treatment (chemotherapy, radiotherapy, immunotherapy or Tyrosine-Kinase inhibitors), treatment duration, stop date of treatment and reason for end of treatment
Time frame: From Baseline, during treatment and follow-up until confirmed progression (of note, for Cohorts 1 and 2, a follow-up post-progression is planned), loss of follow-up or end of the study, assessed up to 5 years maximum
Change in patients' socio-economic and occupational outcomes during treatment and follow-up until confirmed progression (of note, for Cohorts 1 and 2, a follow-up post-progression is planned), loss of follow-up or end of the study using a dedicated self questionnaire on socio-economic and occupational outcomes
Time frame: From Baseline, during treatment and follow-up until confirmed progression (of note, for Cohorts 1 and 2, a follow-up post-progression is planned), loss of follow-up or end of the study, assessed up to 5 years maximum
Groupe Francais De Pneumo-Cancerologie
Other
Acronym: OBSTINATE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04606771
Bronchial Neoplasms, Carcinoma
Duarte, California, United States
View Trial DetailsNCT06644768
Bronchial Neoplasms, Carcinoma, Bronchogenic
La Jolla, California, United States
View Trial DetailsNCT06382116
Bronchial Neoplasms, Carcinoma, Bronchogenic
Guangzhou, Guangdong, China
View Trial DetailsNCT05256290
Advanced Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer
Birmingham, Alabama, United States
View Trial Details